Thymosin Alpha-1 typical research dosing
Across the available literature, Thymosin Alpha-1 is most commonly administered at 900–1800 mcg per dose, 1 time(s) per day, via subcutaneous injection. Clinical studies have used 900 mcg (0.9 mg) to 1800 mcg (1.8 mg) subcutaneously 2–3 times per week. The approved Zadaxin dose is 1.6 mg twice weekly for 6 months in hepatitis B protocols.
Thymosin Alpha-1 unit-conversion table
The number of insulin-syringe units you draw depends on how much bacteriostatic water you used to reconstitute the vial. The table below shows units to draw on a U-100 syringe for a 1.5 mg Thymosin Alpha-1 vial at common reconstitution volumes.
| Diluent (mL) | Concentration | 900 mcg | 1350 mcg | 1800 mcg |
|---|---|---|---|---|
| 1 mL | 1500 mcg/mL | 60.0 units | 90.0 units | 120.0 units |
| 2 mL | 750 mcg/mL | 120.0 units | 180.0 units | 240.0 units |
| 3 mL | 500 mcg/mL | 180.0 units | 270.0 units | 360.0 units |
| 5 mL | 300 mcg/mL | 300.0 units | 450.0 units | 600.0 units |
Thymosin Alpha-1 cycle length
Most reported Thymosin Alpha-1 protocols run 26 weeks on, then 8 weeks off. Cycles are used in research to study washout, receptor sensitivity, and to re-baseline endogenous signaling before re-introducing the compound.
Thymosin Alpha-1 half-life and timing
Thymosin Alpha-1 has a half-life of approximately 2 hours. This influences dose frequency: shorter half-lives often require multiple doses per day to maintain steady-state levels, while longer half-lives can be dosed less frequently.